Equal contribution of pharmacogenetic phenotype and phenoconversion to functional CYP2D6 metabolizer status

被引：0
|
作者：
Scherf-Clavel, M. [1 ]
Frantz, A. [2 ]
Eckert, A. [2 ]
Weber, H. [1 ]
Unterecker, S. [1 ]
Deckert, J. [1 ]
Reif, A. [2 ]
Hahn, M. [2 ,3 ]
机构：
[1] Univ Hosp Wurzburg, Dept Psychiat Psychosomat & Psychotherapy, Ctr Mental Hlth, D-97080 Wurzburg, Germany
[2] Univ Hosp Frankfurt, Dept Psychiat Psychosomat Med & Psychotherapy, D-60528 Frankfurt, Germany
[3] Varisano Hosp Frankfurt Hoechst, Dept Mental Hlth, Frankfurt, Germany
来源：
PHARMACOPSYCHIATRY | 2024年 / 57卷 / 02期
关键词：
D O I：
10.1055/s-0044-1779576
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
33
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [1] Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study
    Maike Scherf-Clavel
    Amelie Frantz
    Andreas Eckert
    Heike Weber
    Stefan Unterecker
    Jürgen Deckert
    Andreas Reif
    Martina Hahn
    International Journal of Clinical Pharmacy, 2023, 45 : 1107 - 1117
  • [2] Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study
    Scherf-Clavel, Maike
    Frantz, Amelie
    Eckert, Andreas
    Weber, Heike
    Unterecker, Stefan
    Deckert, Juergen
    Reif, Andreas
    Hahn, Martina
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (05) : 1107 - 1117
  • [3] CYP2D6 metabolizer status and postoperative analgesia with tramadol
    Wilder-Smith, CH
    Wilkins, J
    ANESTHESIOLOGY, 1999, 91 (3A) : U416 - U416
  • [4] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [5] A response to “Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study”
    Xiang Shang
    International Journal of Clinical Pharmacy, 2023, 45 : 1307 - 1308
  • [6] A response to "Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study"
    Shang, Xiang
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (05) : 1307 - 1308
  • [7] Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status
    Barclay, ML
    Sawyers, SM
    Begg, EJ
    Zhang, M
    Roberts, RL
    Kennedy, MA
    Elliott, JM
    PHARMACOGENETICS, 2003, 13 (10): : 627 - 632
  • [8] ASSOCIATION OF CYP2D6 METABOLIZER STATUS WITH ANTIDEPRESSANT INDUCED MANIA
    Beaupre, Lindsay Melhuish
    Zai, Clement
    Tiwari, Arun
    Mundo, Emanuela
    Shaikh, Sajid
    Tampakeras, Maria
    Freeman, Natalie
    Kennedy, James L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S865 - S865
  • [9] CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Hiken, Eliah J.
    Poweleit, Ethan A.
    Keane, Corey
    Desta, Zeruesenay
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2023, 62 (10): : S197 - S197
  • [10] A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics
    Blake, C. M.
    Kharasch, E. D.
    Schwab, M.
    Nagele, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 394 - 399
12345